Paper19082467
The expression of CRM1 is associated with prognosis in human osteosarcoma.
Yao Y and 8 others. Oncol Rep, 2009. Cited by 138 papers, by iCite.
Cite this record
ConductScience Library. The expression of CRM1 is associated with prognosis in human osteosarcoma. Papers, record 19082467. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19082467
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bone Neoplasms | Major topic |
| Karyopherins | Major topic |
| Osteosarcoma | Major topic |
| Receptors, Cytoplasmic and Nuclear | Major topic |
| Adolescent | |
| Adult | |
| Alkaline Phosphatase | |
| Blotting, Western | |
| Child | |
| Child, Preschool | |
| Female | |
| Humans | |
| Kaplan-Meier Estimate | |
| L-Lactate Dehydrogenase | |
| Male | |
| Middle Aged | |
| Prognosis | |
| Exportin 1 Protein |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT06114004 | Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc) | Background |
Source ClinicalTrials.gov
Cited by98
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 138 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39165691 | Cancer-specific alterations in nuclear matrix proteins determined by multi-omics analyses of ductal carcinoma in situ. | Front Oncol | 2024 | https://conductscience.org/library/papers/39165691 | PubMed |
| 39161560 | Novel-and Not So Novel-Inhibitors of the Multifunctional CRM1 Protein. | Oncol Rev | 2024 | https://conductscience.org/library/papers/39161560 | PubMed |
| 38892287 | Michael Acceptors as Anti-Cancer Compounds: Coincidence or Causality? | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38892287 | PubMed |
| 38783482 | The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials. | Clin Transl Med | 2024 | https://conductscience.org/library/papers/38783482 | PubMed |
| 38302473 | Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma. | Nat Commun | 2024 | https://conductscience.org/library/papers/38302473 | PubMed |
| 38186637 | Treatment of multiple myeloma with selinexor: a review. | Ther Adv Hematol | 2024 | https://conductscience.org/library/papers/38186637 | PubMed |
| 38031942 | CRM1 expression: association with high prognostic value in laryngeal cancer. | Turk J Med Sci | 2023 | https://conductscience.org/library/papers/38031942 | PubMed |
| 36920247 | A general method for quantitative fractionation of mammalian cells. | J Cell Biol | 2023 | https://conductscience.org/library/papers/36920247 | PubMed |
| 36827679 | Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects. | Blood Adv | 2023 | https://conductscience.org/library/papers/36827679 | PubMed |
| 35116322 | Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesis. | Transl Cancer Res | 2021 | https://conductscience.org/library/papers/35116322 | PubMed |
| 34975332 | Verdinexor, a Selective Inhibitor of Nuclear Exportin 1, Inhibits the Proliferation and Migration of Esophageal Cancer via XPO1/c-Myc/FOSL1 Axis. | Int J Biol Sci | 2022 | https://conductscience.org/library/papers/34975332 | PubMed |
| 34944778 | Therapeutic Targeting of Exportin-1 in Childhood Cancer. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34944778 | PubMed |
| 34583979 | Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. | Mol Cancer Ther | 2021 | https://conductscience.org/library/papers/34583979 | PubMed |
| 34575598 | Selinexor and the Selective Inhibition of Nuclear Export: A New Perspective on the Treatment of Sarcomas and Other Solid and Non-Solid Tumors. | Pharmaceutics | 2021 | https://conductscience.org/library/papers/34575598 | PubMed |
| 34562230 | Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study. | Invest New Drugs | 2022 | https://conductscience.org/library/papers/34562230 | PubMed |
| 34502125 | Measuring and Interpreting Nuclear Transport in Neurodegenerative Disease-The Example of C9orf72 ALS. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34502125 | PubMed |
| 34188179 | Disruption of nucleocytoplasmic trafficking as a cellular senescence driver. | Exp Mol Med | 2021 | https://conductscience.org/library/papers/34188179 | PubMed |
| 34165175 | Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19‑positive malignancies. | Oncol Rep | 2021 | https://conductscience.org/library/papers/34165175 | PubMed |
| 33909232 | Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. | Invest New Drugs | 2021 | https://conductscience.org/library/papers/33909232 | PubMed |
| 33856525 | Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity. | J Cancer Res Clin Oncol | 2021 | https://conductscience.org/library/papers/33856525 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALPP | 250 | PubTator's text mining | https://conductscience.org/library/genes/250 | NCBI Gene |
| XPO1 | 7514 | PubTator's text mining | https://conductscience.org/library/genes/7514 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19082467
GET https://conductscience.org/api/papers/v1/19082467/cited_by?page=2